At a glance
ClinicalIndex Comparison RecordN/ACompleted· 608 enrolled
Drug / intervention
Tocilizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Factors Influencing Use of RoActemra® as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO
In Brief
An observational study evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 608 participants across 119 sites.
Detailed Summary
This prospective, multi-center, observational study will evaluate factors influencing the use of tocilizumab (RoActemra/Actemra) as monotherapy in rheumatoid arthritis patients in real life setting. Data will be collected from participants for 12 months following initiation of tocilizumab treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartJan 2012
Primary CompletionSep 2014
TodayJul 2026
First PostedNov 18, 2011
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.6 years ago
Interventions
Tocilizumabbiological
Tocilizumab administered according to prescribing information and normal clinical practice.